Welcome to our dedicated page for Pacira BioSciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences provides a detailed update on its non-opioid pain franchise and growth strategy for the year ended December 31, 2025. EXPAREL remains the core product, with net product sales of $575.1 million, representing 79% of total revenue. ZILRETTA generated net product sales of $116.6 million and iovera° $24.2 million.
The company highlights its “5x30” plan to 2030, targeting double-digit product revenue growth, gross margin improvement and at least five clinical programs and five partnerships. It reports reaching 2.5 million patients in 2025 and adding strategic partnerships for EXPAREL and ZILRETTA.
Pacira expands on its pipeline, led by gene therapy candidate PCRX-201 for knee osteoarthritis, which has Phase 1 data and is in Phase 2 development with RMAT and ATMP designations. It also acquired the remaining stake in GQ Bio Therapeutics and licensed PCRX-2002 from AmacaThera.
The filing describes extensive clinical data supporting EXPAREL, ZILRETTA and iovera°, the IGOR real‑world outcomes registry, manufacturing capacity with Thermo Fisher and internal facilities, and key commercial agreements. It also notes a Paragraph IV settlement that allows limited generic EXPAREL entry starting in early 2030 and a favorable royalty dispute judgment requiring RDF to repay $23.1 million plus $5.2 million interest.
Pacira BioSciences reported modest growth for 2025 and returned to profitability, while laying out guidance for 2026. Total 2025 revenue was $726.4 million, up 4% from 2024, led by EXPAREL net product sales of $575.1 million, a 5% increase.
The company posted 2025 GAAP net income of $7.0 million, or $0.16 per share, compared with a GAAP net loss of $99.6 million in 2024 that included a large goodwill impairment. Non-GAAP net income was $122.3 million, with adjusted EBITDA of $186.5 million, down from $223.9 million.
Pacira repurchased 5.9 million shares in 2025 for $150.0 million, ending the year with 41.1 million shares outstanding and $150.0 million remaining under its authorization. For 2026, it guides to total revenue of $745–$770 million, EXPAREL sales of $600–$620 million and non-GAAP gross margin of 77–79%.
Pacira BioSciences Chief Financial Officer Shawn Cross was granted 49,091 restricted stock units of common stock on February 11, 2026. The award was reported at a price of $0 per share as an acquisition, increasing his directly held common stock to 105,341 shares.
The restricted stock units vest in four equal annual installments beginning on February 15, 2027, if Cross remains in continuous service with Pacira on each vesting date. Each unit represents the right to receive one share of Pacira common stock upon vesting.
Pacira BioSciences Chief Administrative Officer Kristen Williams received an equity award of 54,546 shares of common stock on February 11, 2026. The award is in the form of restricted stock units granted at a price of $0 per share, described as a grant, award, or other acquisition.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as she remains in continuous service with the company on each vesting date. Each unit represents the right to receive one share of Pacira common stock. Following this grant, Williams beneficially owns 185,849 shares of Pacira common stock directly.
Pacira BioSciences, Inc. reported an equity award to Chief Commercial Officer Brendan Teehan. On February 11, 2026, he acquired 51,714 shares of common stock at a price of $0 under a grant classified as an award or other acquisition.
The award represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. After this grant, Teehan directly beneficially owns 100,934.268 shares of Pacira common stock.
RIKER LAUREN reported acquisition or exercise transactions in a Form 4 filing for PCRX. The filing lists transactions totaling 19,273 shares. Following the reported transactions, holdings were 71,586 shares.
SLONIN JONATHAN reported acquisition or exercise transactions in this Form 4 filing.
Pacira BioSciences, Inc. reported that Chief Medical Officer Jonathan Slonin received an equity award of 54,546 shares of common stock on February 11, 2026. The award was granted at a price of $0 per share and is structured as restricted stock units.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as Slonin remains in continuous service with the company on each vesting date. After this grant, he beneficially owns 226,901.175 shares of Pacira common stock directly.
Pacira BioSciences, Inc. reported an equity award to its Chief Executive Officer and director, Frank D. Lee. On February 11, 2026, he acquired 261,818 shares of common stock in the form of restricted stock units granted at a price of $0 per share.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. Following this grant, Lee beneficially owns 660,830.841 shares of Pacira common stock directly.
Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker reported routine equity transactions in company stock. On January 30, 2026, 2,751 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at $20.54 per share. On February 2, 2026, Riker sold 4,000 shares of common stock at a weighted average price of $20.81 per share, executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Riker directly beneficially owned about 52,313.242 shares of Pacira common stock.
Pacira BioSciences Chief Administrative Officer Kristen Williams reported two stock transactions. On January 30, 2026, 17,134 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at a price of $20.54 per share, leaving her with 144,440 shares held directly.
On February 2, 2026, she sold 13,137 Pacira common shares at $20.53 per share in a transaction carried out under a pre-established Rule 10b5-1 trading plan. After this sale, she directly held 131,303 Pacira shares.